GEN Exclusives

More »

GEN News Highlights

More »
Sep 1, 2010

FDA Clears Allergan’s Lumigan 0.01% Eye Drops for Lowering Intraocular Pressure

  • FDA has approved Allergan’s Lumigan® 0.01% bimatoprost solution as first-line therapy for reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The once-daily eye-drop product is an optimized reformulation of Lumigan 0.03%. Allergan says the drug will be available during the fourth quarter of 2010.

    A three-month study with Lumigan 0.01% showed that treatment lowered IOP up to 7 mmHg from baseline in patients with an average baseline of 23.5 mmHg, despite using only one-third of the drug concentration in Lumigan 0.03%.

    Allergan’s eyecare pharmaceuticals portfolio made net sales of $2.1 billion in the year to December 31 2010, up about $100,000 on sales in 2008. During May 2010 the firm reported FDA approval of Zymaxid™ 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis. The firm projects to achieve Lumigan franchise product net sales of $490-$510 million  in 2010.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?